US 2022/0089715 A1 · METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY

Abstract

One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.

Claims20

Dependent claims

-21. (canceled)

A human region variant comprising an FcRn-binding domain, wherein the FcRn-binding domain comprises:

(a) Ala at position 434;
Glu, Arg, Ser, or Lys at position 438;
and Glu, Asp, or Gln at position 440, according to EU numbering;
(b) Ala at position 434;
Arg or Lys at position 438;
and Glu or Asp at position 440, according to EU numbering;
(c) Ile or Leu at position 428;
Ala at position 434;
Ile, Leu, Val, Thr, or Phe at position 436;
Glu, Arg, Ser, or Lys at position 438;
and Glu, Asp, or Gln at position 440, according to EU numbering;
(d) Ile or Leu at position 428;
Ala at position 434;
Ile, Leu, Val, Thr, or Phe at position 436;
Arg or Lys at position 438;
and Glu or Asp at position 440, according to EU numbering;
(e) Leu at position 428;
Ala at position 434;
Val or Thr at position 436;
Glu, Arg, Ser, or Lys at position 438;
and Glu, Asp, or Gln at position 440, according to EU numbering;
or
(f) Leu at position 428;
Ala at position 434;
Val or Thr at position 436;
Arg or Lys at position 438;
and Glu or Asp at position 440, according to EU numbering.

24 more elements

Dependencies are inferred from the claim text.

Methods of neutralizing il-8 biological activity

Life of this patent

Methods of neutralizing il-8 biological activity

Life of this patent

Abstract

Claims20